Interferon-α as the only adjuvant treatment in high-grade osteosarcoma: Long term results of the Karolinska Hospital series

References

• Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91: 1198–1205
   PubMed Web of Science ®Google Scholar
• Gresser I. Antitumor effects of interferon. Acta Oncol 1989; 28: 347–53
   PubMed Web of Science ®Google Scholar
• Strander H. Interferon treatment of human neoplasia. Adv Cancer Res 1986; 46: 1–265
   PubMed Web of Science ®Google Scholar
• Einhorn S, Strander H. Is interferon tissue specific?- Effect of human leukocyte and fibroblast interferons on the growth of lymphoblastoid and osteosarcoma cell lines. J Gen Virol 1977; 35: 573–77
   PubMed Web of Science ®Google Scholar
• Brosjo O. Osteosarcoma and interferon. Studies of human xenografts in the nude mouse. Acta Orthop Scand Suppl 1989; 229: 1–36
   PubMedGoogle Scholar
• Hofmann V, Groscurth P, Morant R, Cserhati M, Honegger HP, von Hochstetter A. Effects of leukocyte interferon (E. coli) on human bone sarcoma growth in vitro and in the nude mouse. Eur J Cancer Clin Oncol 1985; 21: 859–63
   PubMedGoogle Scholar
• Huvos AG. Bone tumors: diagnosis, treatment, and prognosis2nd ed. W.B. Saunders Company, Philadelphia 1991
   Google Scholar
• Harvei S, Solheim O. The prognosis in osteosarcoma: Norwegian National Data. Cancer 1981; 48: 1719–23
   PubMed Web of Science ®Google Scholar
• Lindbom A, Söderberg G, Spjut HJ. Osteosarcoma: a review of 96 cases. Acta Radiol 1961; 56: 1–19
   PubMed Web of Science ®Google Scholar
• Adamson A, Aparisi T, Broström LA, Cantell K, Einhorn S, Hall K, et al. Interferon treatment of osteosarcoma. Pontificiae Acad Scient Scripta Varia 1979; 43: 383–406
   Google Scholar
• Strander H, Bauer HC, Brosjo O, Kreicbergs A, Lindholm J, Nilsonne U, . Adjuvant interferon treatment in human osteosarcoma. Osteosarcoma in adolescents and young adults, G Bennett Humphrey, et al. Kluwer Academic Publishers, Boston 1993; 29–32
   Google Scholar
• Strander H, Bauer HC, Brosjo O, Fernberg JO, Kreicbergs A, Nilsonne U, et al. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol 1995; 34: 877–80
   PubMed Web of Science ®Google Scholar
• Smeland S, Muller C, Alvegard TA, Wiklund T, Wiebe T, Bjork O, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003; 39: 488–94
   PubMed Web of Science ®Google Scholar
• Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9: 422–41
   PubMed Web of Science ®Google Scholar
• Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980; 153: 106–20
   PubMed Web of Science ®Google Scholar
• Cantell K, Hirvonen S, Kauppinen HL, Myllyla G. Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol 1981; 78((Pt A))29–38
   PubMedGoogle Scholar
• Cantell K, Hirvonen S, Koistinen V. Partial purification of human leukocyte interferon on a large scale. Methods Enzymol 1981; 78((Pt A))499–505
   PubMedGoogle Scholar
• Ingimarsson S, Cantell K, Strander H. Side effects of long-term treatment with human leukocyte interferon. J Infect Dis 1979; 140: 560–3
   PubMed Web of Science ®Google Scholar
• Brostrom LA, Adamson U, Filipsson R, Hall K. Longitudinal growth and dental development in osteosarcoma patients. Acta Orthop Scand 1980; 51: 755–9
   PubMed Web of Science ®Google Scholar
• Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987; 5: 21–26
   PubMed Web of Science ®Google Scholar
• Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314: 1600–606
   PubMed Web of Science ®Google Scholar
• Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 1995; 75: 1084–93
   PubMed Web of Science ®Google Scholar
• Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol 1984; 2: 617–24
   PubMed Web of Science ®Google Scholar
• Van Gool AR, Kruit WH, Engels FK, Stoter G, Bannink M, Eggermont AM. Neuropsychiatric side effects of interferon-alfa therapy. Pharm World Sci 2003; 25: 11–20
   PubMedGoogle Scholar
• Borden EC, Lindner D, Dreicer R, Hussein M, Peereboom D. Second-generation interferons for cancer: clinical targets. Semin Cancer Biol 2000; 10: 125–44
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776–90
   PubMed Web of Science ®Google Scholar
• Manara MC, Serra M, Benini P, Picci P, Scotlandi K. Effectiveness of type I IFNs in the treatment of multidrug resistant osteosarcoma cells. Int J Oncol 2004; 24: 365–72
   PubMed Web of Science ®Google Scholar
• Stein U, Walther W, Shoemaker RH. Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. Br J Cancer 1996; 74: 1384–91
   PubMed Web of Science ®Google Scholar
• Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424: 516–23
   PubMed Web of Science ®Google Scholar
• Allen IE, Ross SD, Borden SP, Monroe MW, Kupelnick B, Connelly JE, et al. Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma. J Immunother 2001; 24: 58–65
   PubMed Web of Science ®Google Scholar
• Bjorkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2001; 27: 511–15
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 2002; 95: 389–96
   PubMed Web of Science ®Google Scholar